BMRN BioMarin Pharmaceutical Inc. Stock Quote

BMRN [NASD]

Index	-	P/E	-	EPS (ttm)	-0.37	Insider Own	0.50%	Shs Outstand	181.77M	Perf Week	-1.16%
Market Cap	14.65B	Forward P/E	84.38	EPS next Y	0.93	Insider Trans	-16.21%	Shs Float	181.71M	Perf Month	-6.75%
Income	-67.30M	PEG	-	EPS next Q	-0.11	Inst Own	98.20%	Short Float	5.64%	Perf Quarter	-2.15%
Sales	1.84B	P/S	7.94	EPS this Y	117.90%	Inst Trans	-0.16%	Short Ratio	11.01	Perf Half Y	-5.42%
Book/sh	22.90	P/B	3.44	EPS next Y	273.10%	ROA	13.80%	Target Price	107.11	Perf Year	-35.90%
Cash/sh	5.84	P/C	13.47	EPS next 5Y	32.16%	ROE	20.40%	52W Range	71.35 - 124.52	Perf YTD	-10.22%
Dividend	-	P/FCF	127.63	EPS past 5Y	15.10%	ROI	0.20%	52W High	-36.77%	Beta	0.53
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	15.90%	Gross Margin	71.10%	52W Low	10.34%	ATR	1.70
Employees	3059	Current Ratio	5.30	Sales Q/Q	-3.20%	Oper. Margin	-6.30%	RSI (14)	42.67	Volatility	2.16% 2.06%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-78.30%	Profit Margin	43.10%	Rel Volume	0.71	Prev Close	78.33
Shortable	Yes	LT Debt/Eq	0.26	Earnings	Jul 28 AMC	Payout	0.00%	Avg Volume	930.73K	Price	78.73
Recom	2.00	SMA20	-2.89%	SMA50	-2.13%	SMA200	-1.86%	Volume	661,062	Change	0.51%

Jun-04-21

Resumed

Robert W. Baird

Outperform

$101

Apr-26-21

Resumed

Credit Suisse

Outperform

$102

Mar-04-21

Resumed

Guggenheim

Buy

Mar-01-21

Upgrade

Evercore ISI

In-line → Outperform

$90 → $100

Aug-20-20

Downgrade

William Blair

Outperform → Mkt Perform

Aug-20-20

Downgrade

Citigroup

Buy → Neutral

$148 → $86

Aug-19-20

Downgrade

Stifel

Buy → Hold

$127 → $100

Aug-19-20

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

Aug-19-20

Downgrade

Evercore ISI

Outperform → In-line

Jul-08-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$125

Jul-06-20

Reiterated

Citigroup

Buy

$105 → $148

Jan-28-20

Initiated

BMO Capital Markets

Market Perform

Jan-27-20

Initiated

BMO Capital Markets

Market Perform

Jan-24-20

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$111 → $113

Nov-27-19

Upgrade

Barclays

Equal Weight → Overweight

$86 → $98

Nov-12-19

Initiated

SunTrust

Buy

$110

Oct-17-19

Resumed

BofA/Merrill

Buy

$90

May-23-19

Resumed

Citigroup

Buy

Apr-09-19

Resumed

Raymond James

Outperform

Jan-02-19

Downgrade

Raymond James

Outperform → Mkt Perform

Jul-28-21 08:19PM	BioMarin Stock Bounces Back With Solid Earnings Barrons.com
06:15PM	BioMarin Pharmaceutical (BMRN) Tops Q2 Earnings and Revenue Estimates Zacks
04:03PM	BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates PR Newswire
12:00PM	BioMarin (BMRN) Upgraded to Strong Buy: Here's What You Should Know Zacks
10:00AM	Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View Zacks
Jul-27-21 11:14AM	Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY Zacks
Jul-23-21 11:06AM	Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy Zacks
Jul-21-21 04:22PM	Novartis' (NVS) Q2 Earnings Top Estimates as Businesses Recovers Zacks
03:02PM	Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for Zacks
10:01AM	BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstrating Continued, Durable Clinical Benefit PR Newswire
09:31AM	Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX Zacks
Jul-20-21 07:40AM	Vertex (VRTX) Initiates Phase II Study on Pain Candidate Zacks
Jul-19-21 01:16PM	BioMarin Unveils News Data From Late-Stage Hemophilia A Gene Therapy Candidate Benzinga
11:00AM	BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress PR Newswire
Jul-16-21 11:22AM	Synlogic's (SYBX) Begins Phase I Study for PKU Treatment Zacks
10:52AM	BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy Zacks
Jul-15-21 09:39AM	BioMarin Expects EMA's CHMP Opinion In 1H 2022 For Its Hemophilia A Gene Therapy, FDA Resubmission In 2Q'22 Benzinga
08:31AM	European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A PR Newswire
Jul-14-21 08:30AM	BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET PR Newswire
Jul-12-21 04:46PM	10 Stocks Stanley Druckenmiller is Selling Insider Monkey
Jul-05-21 07:48AM	QIAGEN (QGEN), Sysmex Ink Cancer Companion Diagnostics Deal Zacks
Jul-02-21 09:05AM	BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress PR Newswire
01:47AM	How Many BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
Jun-29-21 11:07AM	BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU Zacks
Jun-28-21 11:18AM	BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism Zacks
08:31AM	BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A PR Newswire
Jun-25-21 01:30PM	EMA's Advisory Committee Backs Approval Of BioMarin's Dwarfism Candidate Benzinga
07:29AM	BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close PR Newswire
Jun-21-21 12:17PM	Is BioMarin Pharmaceutical Inc. (BMRN) A Good Stock To Buy? Insider Monkey
Jun-15-21 08:30AM	BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference PR Newswire
Jun-02-21 12:19PM	Heres Why ClearBridge Sold its BioMarin Pharmaceutical (BMRN) Position Insider Monkey
May-27-21 08:30AM	BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire
May-25-21 10:49AM	BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review Zacks
09:07AM	BioMarin Gets EMA Permit for Accelerated Assessment of Valoctocogene Roxaparvovec SmarterAnalyst
May-24-21 12:11PM	EMA Grants BioMarin's Request For Speedy Review of Hemophilia A Gene Therapy Benzinga
08:31AM	European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A PR Newswire
May-19-21 01:05PM	Five-Year Data Of BioMarin's Hemophilia Gene Therapy Shows Sustained Benefit Benzinga
08:31AM	BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A PR Newswire
May-18-21 08:30AM	BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire
May-12-21 08:31AM	BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting PR Newswire
May-04-21 04:03PM	Was The Smart Money Right About BioMarin (BMRN)? Insider Monkey
May-03-21 08:30AM	BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire
04:38AM	Estimating The Fair Value Of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Simply Wall St.
Apr-30-21 09:58AM	BioMarin (BMRN) Q1 Earnings Beat, FDA Delays Vosoritide Decision Zacks
08:49AM	BioMarin Reports Better-Than-Expected 1Q Results SmarterAnalyst
Apr-29-21 11:31PM	Biomarin Pharmaceutical Inc (BMRN) Q1 2021 Earnings Call Transcript Motley Fool
05:25PM	BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates Zacks
04:03PM	BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates PR Newswire
02:30PM	BioMarin Pharmaceutical, Inc. to Host Earnings Call ACCESSWIRE
Apr-28-21 08:31AM	Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases PR Newswire
Apr-22-21 12:33PM	Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-15-21 08:31AM	BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice PR Newswire
Apr-13-21 08:30AM	BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET PR Newswire
Mar-30-21 01:23PM	Replay: Investing in Alzheimers Treatment Jupiter Orphan Therapeutics CEO Joins Fireside Chat IPO-Edge.com
Mar-27-21 11:31AM	BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound? Zacks
Mar-23-21 01:53PM	Investing in Alzheimers Treatment: Join Jupiter Orphan Therapeutics for Fireside Chat March 30 IPO-Edge.com
Mar-21-21 10:02PM	Is BioMarin (BMRN) Stock A Buy or Sell? Insider Monkey
Mar-20-21 11:15AM	BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide PR Newswire
Mar-19-21 10:50PM	BIOMARIN INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN Business Wire
Mar-12-21 11:29AM	7 Pharmaceutical Stocks Working on Their Next Blockbuster InvestorPlace
Mar-09-21 09:05AM	BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag Zacks
Mar-08-21 12:05PM	BioMarin's Hemophilia Gene Therapy Scores RMAT Designation In US Benzinga
08:31AM	BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A PR Newswire
Mar-03-21 08:31AM	BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia PR Newswire
Feb-26-21 10:50PM	BIOMARIN INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN PR Newswire -5.30%
12:02PM	Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript Motley Fool
09:16AM	BioMarin (BMRN) Q4 Earnings Beat, 2021 Sales View Dull Zacks
Feb-25-21 02:30PM	BioMarin Pharmaceutical, Inc. to Host Earnings Call ACCESSWIRE
Feb-24-21 10:09AM	Biomarin Pharmaceutical's Earnings Outlook Benzinga
08:30AM	BioMarin to Participate in Four Upcoming Virtual Investor Conferences PR Newswire
Feb-18-21 04:01PM	BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors PR Newswire
Feb-11-21 11:40AM	ALXN vs. BMRN: Which Stock Is the Better Value Option? Zacks
Feb-06-21 01:52AM	Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 22% Profit? Simply Wall St.
Jan-28-21 09:00AM	BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index PR Newswire
Jan-26-21 11:40AM	ALXN vs. BMRN: Which Stock Should Value Investors Buy Now? Zacks
08:30AM	BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET PR Newswire
Jan-22-21 07:55AM	Is Now A Good Time To Buy BioMarin Stock? Motley Fool
Jan-15-21 10:50PM	BIOMARIN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of BioMarin Pharmaceutical Inc. - BMRN Business Wire
Jan-12-21 09:24AM	Stock Market News for Jan 12, 2021 Zacks
Jan-11-21 10:58AM	BioMarin's stock tumbles 6% after sharing data about experimental hemophilia A drug MarketWatch -9.59%
10:14AM	BioMarins One-Year Data on Its Hemophilia Gene-Therapy Looked Good. Can It Win FDA Approval? Barrons.com
08:37AM	BioMarin (BMRN) Reveals 1-Year Data on Hemophilia Gene Therapy Zacks
08:11AM	Gene-Therapy Firm Bluebird Bio Is Spinning Off Its Cancer Programs Barrons.com
Jan-10-21 06:44PM	BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set PR Newswire
Jan-07-21 11:40AM	ALXN or BMRN: Which Is the Better Value Stock Right Now? Zacks
Jan-05-21 08:30AM	BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire
Jan-04-21 08:42AM	Is BioMarin Pharmaceutical (BMRN) Stock a Buy For 2021? Insider Monkey
Dec-31-20 09:24AM	Is BioMarin Pharmaceutical (BMRN) a Smart Long-term Buy? Insider Monkey
Dec-21-20 08:29AM	BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study PR Newswire
Dec-18-20 12:14PM	The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals Zacks
Dec-17-20 04:21PM	12 Best Large Biotech Stocks to Buy Now Insider Monkey
09:42AM	4 Biotechs That Could Be Potential Acquisition Targets in 2021 Zacks
Dec-14-20 01:38PM	Is BMRN A Good Stock To Buy Now? Insider Monkey
Dec-09-20 04:02PM	Top Biotech Stocks for Q1 2021 Investopedia
Dec-05-20 11:32AM	Why Is BioMarin (BMRN) Up 6.1% Since Last Earnings Report? Zacks
Dec-01-20 08:30AM	BioMarin to Participate in Two Upcoming Virtual Investor Conferences PR Newswire
Nov-24-20 03:35PM	SHAREHOLDER ALERT: BMRN RCL LOOP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE
03:00PM	BMRN Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds BioMarin Pharmaceutical Inc. Investors of Class Action and Deadline: November 24, 2020 ACCESSWIRE
11:39AM	Pfizer (PFE) Begins Phase III Study on Hemophilia Candidate Zacks
10:15AM	Lawsuits Filed Against BMRN, BIIB and YY - Jakubowitz Law Pursues Shareholders Claims ACCESSWIRE

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; and Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; vosoritide that is in Phase III clinical trial for the treatment of achondroplasia, a form of disproportionate short stature in humans; BMN 307, an AAV5 mediated gene therapy, which is in phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; BMN 331 for the treatment of hereditary angioedema; BMN 255 for the treatment of chronic renal disease; and BMN 351 for the treatment of Duchenne Muscular Dystrophy. The company has collaboration and license agreements with Sarepta Therapeutics, Asubio Pharma Co., Ltd., and DiNAQOR AG. The company serves specialty pharmacies, hospitals, and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration with Allen Institute. BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIENAIME JEAN JACQUES	Chief Executive Officer	Jun 21	Option Exercise	37.46	1,000	37,460	304,839	Jun 23 05:04 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 10	Option Exercise	26.49	8,513	225,509	312,352	May 12 07:21 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 10	Sale	77.29	8,513	657,970	303,839	May 12 07:21 PM
Mueller Brian	EVP, Chief Financial Officer	May 07	Option Exercise	28.23	6,709	189,395	38,066	May 11 07:42 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 07	Option Exercise	26.49	25,000	662,250	328,839	May 10 09:07 PM
Mueller Brian	EVP, Chief Financial Officer	May 07	Sale	79.50	6,709	533,366	31,357	May 11 07:42 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 07	Sale	78.12	25,000	1,953,121	303,839	May 10 09:07 PM
MEIER RICHARD A	Director	May 06	Option Exercise	26.49	15,000	397,350	99,340	May 07 07:48 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 06	Option Exercise	26.49	25,000	662,250	328,839	May 10 09:07 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	May 06	Sale	78.29	25,000	1,957,199	303,839	May 10 09:07 PM
MEIER RICHARD A	Director	May 06	Sale	78.38	5,068	397,245	94,272	May 07 07:48 PM
Davis George Eric	EVP, General Counsel	May 03	Sale	78.30	4,673	365,896	64,108	May 04 08:27 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 30	Option Exercise	37.46	1,000	37,460	303,498	May 03 08:24 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 23	Option Exercise	26.49	10,000	264,900	312,498	Apr 26 08:44 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 23	Sale	79.34	10,000	793,400	302,498	Apr 26 08:44 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 22	Option Exercise	26.49	10,000	264,900	312,498	Apr 26 08:44 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Apr 22	Sale	78.91	10,000	789,100	302,498	Apr 26 08:44 PM
Davis George Eric	EVP, General Counsel	Apr 19	Option Exercise	26.49	2,709	71,761	71,149	Apr 20 09:53 PM
Davis George Eric	EVP, General Counsel	Apr 19	Sale	79.58	2,709	215,582	68,440	Apr 20 09:53 PM
LAWLIS V BRYAN	Director	Apr 15	Option Exercise	26.49	7,500	198,675	26,350	Apr 19 04:09 PM
LAWLIS V BRYAN	Director	Apr 15	Sale	76.90	7,500	576,750	18,850	Apr 19 04:09 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Apr 08	Sale	78.81	1,537	121,131	58,250	Apr 09 05:57 PM
Mueller Brian	EVP, Chief Financial Officer	Apr 01	Sale	76.30	5,692	434,300	31,016	Apr 02 07:35 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 24	Sale	76.30	1,181	90,110	61,439	Mar 26 05:45 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Mar 18	Sale	77.99	1,308	102,011	64,133	Mar 19 09:01 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 12	Option Exercise	26.49	7,000	185,430	302,652	Mar 15 08:26 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 12	Sale	77.10	7,000	539,700	295,652	Mar 15 08:26 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 11	Option Exercise	26.49	7,000	185,430	302,652	Mar 15 08:26 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Mar 11	Sale	77.68	7,000	543,760	295,652	Mar 15 08:26 PM
GREY MICHAEL G	Director	Mar 05	Option Exercise	26.49	5,000	132,450	47,840	Mar 09 05:59 PM
GREY MICHAEL G	Director	Mar 05	Sale	76.28	5,000	381,400	42,840	Mar 09 05:59 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 19	Option Exercise	26.49	7,000	185,430	302,552	Feb 22 08:38 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 19	Sale	83.58	7,000	585,060	295,552	Feb 22 08:38 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 18	Option Exercise	26.49	7,000	185,430	302,552	Feb 19 09:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 18	Sale	85.08	7,000	595,560	295,552	Feb 19 09:22 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 17	Option Exercise	26.49	8,000	211,920	303,552	Feb 18 09:45 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Feb 17	Sale	84.54	8,000	676,320	295,552	Feb 18 09:45 PM
LAWLIS V BRYAN	Director	Feb 16	Option Exercise	26.49	7,500	198,675	26,350	Feb 18 06:43 PM
LAWLIS V BRYAN	Director	Feb 16	Sale	87.41	7,500	655,575	18,850	Feb 18 06:43 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 29	Option Exercise	26.49	8,334	220,768	303,886	Feb 01 07:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 29	Sale	82.67	8,334	688,972	295,552	Feb 01 07:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 28	Option Exercise	26.49	8,333	220,741	303,885	Feb 01 07:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 28	Sale	82.91	8,333	690,889	295,552	Feb 01 07:00 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 27	Option Exercise	26.49	8,333	220,741	303,885	Jan 28 07:35 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Jan 27	Sale	85.49	8,333	712,388	295,552	Jan 28 07:35 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Dec 29	Sale	88.18	1,500	132,270	295,552	Dec 30 08:02 PM
BIENAIME JEAN JACQUES	Chief Executive Officer	Dec 28	Sale	88.77	1,500	133,155	297,052	Dec 30 08:02 PM
Ajer Jeffrey Robert	EVP, Chief Commercial Officer	Oct 14	Sale	79.91	2,121	169,489	61,281	Oct 15 07:17 PM
HERON ELAINE J	Director	Oct 07	Option Exercise	26.49	15,000	397,350	66,968	Oct 08 08:35 PM
PYOTT DAVID E I	Director	Aug 31	Buy	78.26	12,800	1,001,715	30,740	Sep 01 09:44 PM
GREY MICHAEL G	Director	Aug 03	Option Exercise	26.49	2,500	66,225	45,340	Aug 05 06:56 PM
GREY MICHAEL G	Director	Aug 03	Sale	120.35	2,500	300,875	42,840	Aug 05 06:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience